StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ:BLPH opened at $0.06 on Friday. Bellerophon Therapeutics has a 52-week low of $0.03 and a 52-week high of $0.10. The stock has a fifty day moving average of $0.04 and a 200 day moving average of $0.05. The firm has a market capitalization of $672,650.00, a price-to-earnings ratio of -0.07 and a beta of 0.71.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.